Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

78 BUCILLAMINE
Rash
(2002): Kishimoto N+, Nihon Kokyuki Gakkai Zasshi 40(4), 321
Subcorneal pustular dermatosis (Sneddon-Wilkinson)
(2001): Kishimoto K+, Eur J Dermatol 11(1), 41
Toxic epidermal necrolysis
(2005): Izumi A+, JDermatol32(5), 397
Nails
Nails – dystrophy
(1995): Ishizaki C+, Int J Dermatol 34(7), 493
(1991): Ichikawa Y+, Tokai J Exp Clin Med T(5-6), 203
Other
Adverse effects
(2005): Nagashima M+, Clin Exp Rheumatol 23(1), 27 (23%)
(1993): Inokuma S+, Ryumachi 33(4), 316
Cough
(2001): Lee YH+, Korean J Intern Med 16(1), 36
(2001): Matsushima H+, Nihon Kokyuki Gakkai Zasshi 39(1), 55
(1995): Ogawa H+, Respir Med 89(3), 219
(1992): Hara A+, Nihon Kyobu Shikkan Gakkai Zasshi 30(9), 1743
Fever
(2002): Kishimoto N+, Nihon Kokyuki Gakkai Zasshi 40(4), 321
(2002): Miwa Y+, Ryumachi 42(1), 70
(2001): Matsushima H+, Nihon Kokyuki Gakkai Zasshi 39(1), 55
(1992): Hara A+, Nihon Kyobu Shikkan Gakkai Zasshi 30(9), 1743
Gynecomastia
(2002): Sakai Y+, Ann Plast Surg 49(2), 193
Nephrotoxicity
(2006): Hoshino J+, Nephron Clin Pract 104(1), c15
(2004): Ohno I+, Nippon Rinsho 62(10), 1919
BUCLIZINE
Trade names: Aphilan; Bucladin-S; Buclixin; Longifene; Odetin;
Postafeno; Vibazina; Vibazine
Indications: Motion sickness, nausea/vomiting
Category: Histamine H1 receptor antagonist
Half-life: N/A
Clinically important, potentially hazardous interactions
with: aprobarbital, butabarbital, chloral hydrate, ethchlorvynol,
mephobarbital, pentobarbital, phenobarbital, phenothiazines,
primidone, secobarbital, zolpidem
Mucosal
Xerostomia
BUDESONIDE
Reactions
Trade names: Pulmicort Turbuhaler (AstraZeneca); Rhinocort
(AstraZeneca)
Indications: Asthma, rhinitis
Category: Corticosteroid, inhaled
Half-life: N/A
Clinically important, potentially hazardous interactions
with: ketoconazole, live vaccines, oral contraceptives
Skin
Acne
Adverse effects
Reactions
(2003): Coghlan D+, Paediatr Drugs 5(10), 685 (rare)
(2003): Delacourt C+, Respir Med 97, S27
(2001): Reichel W+, Int J Clin Pract 55(2), 100
(2001): Terzano C+, Eur Rev Med Pharmacol Sci 5(1), 17
Allergic reactions (sic)
(2000): Bircher AJ+, Dermatology 200(4), 349
(1995): Lepoittevin JP+, Arch Dermatol 131(1), 31
(1993): Fedler R+, Hautarzt 44(2), 91
Angioedema
(2003): Pirker C+, Contact Dermatitis 49(2), 77
Bruising
(2001): Berend N+, Respirology 6(3), 237
Burning
Dermatitis
(1997): Vestergaard L+, Ugeskr Laeger (Danish) 159, 5662
(1993): Hisa T+, Contact Dermatitis 28, 174
(1993): Noda H+, Contact Dermatitis 28(4), 212 (5 cases)
(1991): Dunkel FG+, Contact Dermatitis 25(2), 97 (2 cases)
(1991): Gamboa PM+, Contact Dermatitis 24(3), 227
(1991): Piraccini BM+, Contact Dermatitis 24(1), 54
Edema of lip
(2003): Pirker C+, Contact Dermatitis 49(2), 77
Exanthems
(2000): Bircher AJ+, Dermatology 200(4), 349
Pruritus
(2003): Pirker C+, Contact Dermatitis 49(2), 77
Rash (sic)
(2003): Kilpio K+, Allergy 58(11), 1131
(1993): Hisa T+, Contact Dermatitis 28(3), 174
Mucosal
Oral candidiasis
(1984): Clissold SP+, Drugs 28, 485
Eyes
Eyelid edema
(2003): Pirker C+, Contact Dermatitis 49(2), 77
Other
Anaphylactoid reactions/Anaphylaxis
(2000): Heeringa M+, BMJ 321(7266), 927
Cough
(2003): Dubus JC+, Fundam Clin Pharmacol 17(5), 627
BUMETANIDE
Trade names: Bumedyl; Bumex (Roche); Burinex; Fondiuran;
Fontego; Lunetoron; Miccil; Primex
Indications: Edema associated with congestive heart failure
Category: Diuretic, loop
Half-life: 1–1.5 hours
Clinically important, potentially hazardous interactions
with: amikacin, aminoglycosides, digoxin, gentamicin, kanamycin,
neomycin, streptomycin, tobramycin
Reactions
Skin
Allergic reactions (sic)
Bullous dermatitis
(1990): Leitao EA+, JAmAcadDermatol23, 129
Bullous pemphigoid
(1998): Boulinguez S+, Br J Dermatol 138, 549
Dermatitis
(1989): Moller NE+, Contact Dermatitis 20, 393
Diaphoresis (0.1%)